Skip to content

US · MBRX · BIOTECHNOLOGY

Moleculin Biotech, Inc. (MBRX) intrinsic value and stock valuation

$7.74as of 2026-11-21 · Mkt cap 2.08M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Moleculin Biotech, Inc. DCF and intrinsic value

InvestorsCraft values MBRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MBRX’s statements →

Moleculin Biotech, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77007 moleculin.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-33.56M
20152025
Free cash flow
-$-22.73M
20152025
Total equity
$15M-3.4% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-25.1M-$-26.64M-$-29.63M-$-30.64M-$-22.97M
Net income-$-33.56M-$-21.76M-$-29.77M-$-29.02M-$-15.89M
EPSd-$-28.44M-$-155.43M-$-372.13M-$-362.75M-$-227M
Operating cash flow-$-22.73M-$-23.86M-$-24.1M-$-27.64M-$-18.95M
Capital expenditure$0.00-$-10K-$-120K-$-70K-$-20K
Free cash flow-$-22.73M-$-23.88M-$-24.23M-$-27.71M-$-18.97M
Total assets$22.1M$16.9M$38.2M$57.4M$84.1M
Total debt$360K$480K$570K$450K$160K
Net debt-$-8.52M-$-3.8M-$-22.98M-$-42.69M-$-70.74M
Total equity$15M$5.98M$26.1M$52.2M$79M
Cash and short-term investments$8.88M$4.28M$23.6M$43.2M$70.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$90K$0.00$0.00$0.00$0.00
Gross profit-$-90K$0.00$0.00$0.00$0.00
Research and development expenses$15.9M$17.7M$19.5M$19M$14.4M
Selling, general and administrative expenses$9.12M$8.79M$10M$11.5M$8.39M
Other expenses$90K$130K$130K$130K$160K
Operating expenses$25.1M$26.6M$29.6M$30.6M$23M
Cost and expenses$25.1M$26.6M$29.6M$30.6M$23M
Interest income$100K$550K$1.37M$240K$310K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$90K$130K$130K$130K$160K
Ebitda-$-33.47M-$-21.64M-$-29.64M-$-28.89M-$-15.73M
Operating income-$-25.1M-$-26.64M-$-29.63M-$-30.64M-$-22.97M
Total other income/expenses, net-$-8.46M$4.88M-$-140K$1.61M$7.07M
Income before tax-$-33.56M-$-21.76M-$-29.77M-$-29.02M-$-15.89M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-33.56M-$-21.76M-$-29.77M-$-29.02M-$-15.89M
Weighted average shares outstanding$1.18M$140K$80K$80K$70K
Weighted average diluted shares outstanding$1.18M$140K$80K$80K$70K
Balance sheet
20252024202320222021
Cash and short-term investments$8.88M$4.28M$23.6M$43.2M$70.9M
Net receivables$10K$0.00$0.00$0.00$40K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.69M$5.19M$26.3M$45.6M$72.5M
Property, plant and equipment, net$310K$580K$800K$680K$450K
Goodwill and intangible assets$11.2M$11.2M$11.2M$11.2M$11.2M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$12.4M$11.7M$11.9M$11.8M$11.6M
Total assets$22.1M$16.9M$38.2M$57.4M$84.1M
Accounts payable$3.51M$2.03M$2.5M$2.1M$1.36M
Short-term debt$140K$120K$100K$120K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.85M$5.36M$6.82M$4.82M$3.62M
Long-term debt$220K$360K$470K$340K$60K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$270K$5.59M$5.33M$410K$1.48M
Capital lease obligations$220K$480K$570K$450K$60K
Total liabilities$7.12M$11M$12.1M$5.23M$5.1M
Common stock$0.00$0.00$30K$30K$30K
Retained earnings-$-206M-$-153.37M-$-131.6M-$-101.83M-$-72.81M
Accumulated other comprehensive income (loss)$10K-$-40K-$-10K$10K$40K
Total equity$15M$5.98M$26.1M$52.2M$79M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$360K$480K$570K$450K$160K
Net debt-$-8.52M-$-3.8M-$-22.98M-$-42.69M-$-70.74M
Cash flow statement
20252024202320222021
Net income-$-33.56M-$-21.76M-$-29.77M-$-29.02M-$-15.89M
Depreciation and amortization$90K$130K$130K$130K$160K
Stock-based compensation$1.66M$1.73M$1.98M$2.27M$2.37M
Change in working capital$560K$230K$1.62M$220K$1.04M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.33M-$-470K$400K$730K$230K
Net cash provided by operating activities-$-22.73M-$-23.86M-$-24.1M-$-27.64M-$-18.95M
Investments in property, plant and equipment$0.00-$-10K-$-120K-$-70K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-10K-$-120K-$-70K-$-20K
Common stock issued$27.3M$4.66M$4.17M$0.00$74.7M
Common stock repurchased$0.00$0.00$0.00-$-20K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.3M$4.63M$4.65M-$-20K$74.7M
Net change in cash$4.6M-$-19.27M-$-19.59M-$-27.76M$55.7M
Cash at end of period$8.88M$4.28M$23.6M$43.2M$70.9M
Operating cash flow-$-22.73M-$-23.86M-$-24.1M-$-27.64M-$-18.95M
Capital expenditure$0.00-$-10K-$-120K-$-70K-$-20K
Free cash flow-$-22.73M-$-23.88M-$-24.23M-$-27.71M-$-18.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Moleculin Biotech, Inc.

        Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

        CEO
        Walter V. Klemp
        Employees
        17
        Beta
        1.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Moleculin Biotech, Inc. (MBRX)?

        InvestorsCraft does not currently publish an intrinsic value for MBRX. How the IC value is calculated.

        Is MBRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for MBRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.